J&J's Reminyl Adds Mortality Precaution For Mild Cognitive Impairment
This article was originally published in The Pink Sheet Daily
Executive Summary
The Precautions section of labeling cites two Reminyl studies in patients with mild cognitive impairment in which the treatment-group mortality rate exceeded that of the placebo arm. J&J issues a "Dear Health Care Professional" letter alerting prescribers to the revised labeling.
You may also be interested in...
Reminyl Gets New Name – Razadyne – Ahead Of ER Launch
The name change for the Alzheimer's product follows reports of medication errors with Sanofi-Aventis' diabetes product Amaryl. J&J agreed to change the name prior to launching the extended-release version of galantamine, which will be available in pharmacies in May.
Reminyl Gets New Name – Razadyne – Ahead Of ER Launch
The name change for the Alzheimer's product follows reports of medication errors with Sanofi-Aventis' diabetes product Amaryl. J&J agreed to change the name prior to launching the extended-release version of galantamine, which will be available in pharmacies in May.
Reminyl Safety Signal Reported In Two Cognitive Impairment Studies
FDA and foreign health authorities are investigating mortality rates from two galantamine studies in the treatment of mild cognitive impairment, Johnson & Johnson says. The studies did not demonstrate Reminyl efficacy in the indication.